ANAB News & Analysis
2 articles
Market Mood
AnaptysBio (ANAB) Earnings Miss by $0.34 in Latest Report
AnaptysBio (ANAB) reported earnings that missed estimates by $0.34. Revenue also fell short of expectations, impacting overall financial performance. These results indicate potential challenges for AnaptysBio in meeting market projections. This news is relevant for investors as it may affect stock performance and investor confidence in AnaptysBio's future profitability.
Read More: AnaptysBio (ANAB) Earnings Miss by $0.34 in Latest Report
AnaptysBio (ANAB) Price Target Reduced to $93 Amid Spinoff Completion
AnaptysBio, Inc. (ANAB) has had its price target cut by Piper Sandler from $95 to $93 while maintaining an Overweight rating. This adjustment followed the completion of the First Tracks Biotherapeutics (TRAX) spinoff announced in April 2026, transitioning ANAB to operate as a royalty management company. Additionally, on April 24, the Delaware Chancery Court dismissed a breach of contract claim against AnaptysBio by Tesaro, affirming that the company did not repudiate its agreements with Tesaro regarding Jemperli. These developments could influence investor sentiment and market performance for ANAB.
Read More: AnaptysBio (ANAB) Price Target Reduced to $93 Amid Spinoff Completion